InVivo Therapeutics Holdings Corp. announced that it has completed enrollment in the INSPIRE 2.0 Study for patients with acute spinal cord injury. The 20-patient study is a randomized, controlled trial featuring 10 subjects in each study arm, designed to enhance the existing clinical evidence for the Neuro-Spinal Scaffold from the Company's INSPIRE 1.0 study.
InVivo Therapeutics Holdings Corp.
Equities
NVIV
US46186M6057
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.34 USD | -2.86% |
|
-2.86% | -53.42% |
Apr. 16 | North American Morning Briefing : Powell Comments, -2- | DJ |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-53.42% | 1.06M | |
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |
- Stock Market
- Equities
- NVIV Stock
- News InVivo Therapeutics Holdings Corp.
- InVivo Therapeutics Holdings Corp. Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study